A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 25 mg With Those of Enbrel Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2014
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms SPH
- Sponsors Hanwha Chemical
- 03 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2010 New trial record